According to a recent LinkedIn post from Circulate, CEO Dr. Brad Younggren appeared on the Human Sync Podcast to discuss Therapeutic Plasma Exchange (TPE) in the context of preventive and longevity medicine. The post points to discussion of how TPE may address circulating toxins, inflammatory markers, and microplastics, as well as how biomarkers might guide treatment frequency.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also references current human trial data and upcoming research on circulatory-based interventions, suggesting Circulate is positioning itself around evidence-informed applications of TPE. For investors, this emphasis on clinical data and longevity-focused use cases may indicate a strategy aimed at capturing demand in the emerging healthspan and preventive medicine markets, where regulatory clarity, reimbursement pathways, and demonstrable outcomes will be key drivers of long-term commercial potential.